PixarBio Corporation’s Dr. Taunia Markvicka And Glenn Reiser To Discuss Breakthrough Data On Morphine Strength Non-Addictive Pain Treatment™ Neurorelease™ At The 2016 Congress Of Neurological Surgeons Spine Summit Held In Orlando, FL March 17-18, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation today announced that Dr. Taunia Markvicka its Chief Commercial Officer and Glenn Reiser its Director, Business Development will be available to discuss the company’s breakthrough Morphine Strength Non-Addictive Pain Treatment™ at the 2016 Congress of Neurological Surgeons Spine Summit meeting on Thursday, March 17, 2016 and Friday March 18, 2016 in Orlando, FL.

“and we’re proud to have delivered on their challenge around novel treatments for pain, epilepsy and spinal cord injury”

Please stop by PixarBio Corporation’s booth, #318, at Exhibit Hall on Floor One:

PixarBio Corporation new CCO Dr. Taunia Markvicka said, “This summit on innovation in the spine and peripheral nerve surgery is perfectly aligned with PixarBio’s mission. Attendees will see PixarBio’s emerging options to replace opioids/opiates in the clinic. Our team has decades of experience in neuroscience and specifically pain, which has led to a breakthrough morphine strength non-addictive pain treatment that will be on the market before you know it. Time is of the essence, and there is a lot to do to prepare a product launch.”

“Market demand for non-addictive pain treatment for post-op pain related to spine surgery is significant for a 14-day pain treatment. With 81% of surveyed spine surgeons in agreement, NeuroRelease™ is the perfect fit to treat post-op pain in spine surgeries. We are equally pleased the market is demanding 14-day coverage as optimal post-surgical pain treatment for knee replacement, hip replacement, shoulder surgery, and C-section surgical procedures,” said PixarBio Corporation Director, Business Development Glenn Reiser.

“The 2016 CNS- Spine Summit is an excellent opportunity for PixarBio to reinforce our team’s lead position in innovative neuroscience. Spine surgeons from around the world gather to discuss the summit’s focus "Global Challenges, Universal Solutions" and we’re proud to have delivered on their challenge around novel treatments for pain, epilepsy and spinal cord injury,” said PixarBio CEO Frank Reynolds.

About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.